Saltar al contenido principal
Etiqueta
Case Study

Post-Market Clinical Follow-Up Studies in 5 European Countries

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

Infectious Disease
Respiratory/ENT
Download the PDF

Challenge

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

‍

Solution

IQVIA Consumer Health and ObvioHealth designed and conducted all five of these post-market clinical follow-up studies, which were successfully executed in multiple countries across Europe. All study materials were translated into the primary languages spoken in each study’s location.

Digital recruitment for all five studies was designed to target a population that had used the nasal spray products in the past 6 months.  

Each study called for participants to complete questionnaires, which were designed to be simple and intuitive to keep compliance rates high. This also allowed for participants to report any adverse events or side effects experienced from using the product.

‍

Results

Recruitment on all these studies was completed below projected budget. The studies reached completion before their targeted end dates, with an average duration of 48 days.

The sponsor was able to gain valuable insights into participant use and satisfaction with the product.

Case Study

Post-Market Clinical Follow-Up Studies in 5 European Countries

Infectious Disease
Respiratory/ENT
Download the PDF

Challenge

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

‍

Solution

IQVIA Consumer Health and ObvioHealth designed and conducted all five of these post-market clinical follow-up studies, which were successfully executed in multiple countries across Europe. All study materials were translated into the primary languages spoken in each study’s location.

Digital recruitment for all five studies was designed to target a population that had used the nasal spray products in the past 6 months.  

Each study called for participants to complete questionnaires, which were designed to be simple and intuitive to keep compliance rates high. This also allowed for participants to report any adverse events or side effects experienced from using the product.

‍

Results

Recruitment on all these studies was completed below projected budget. The studies reached completion before their targeted end dates, with an average duration of 48 days.

The sponsor was able to gain valuable insights into participant use and satisfaction with the product.

Case Study

Post-Market Clinical Follow-Up Studies in 5 European Countries

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

Infectious Disease
Respiratory/ENT
Download the PDF

Challenge

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

‍

Solution

IQVIA Consumer Health and ObvioHealth designed and conducted all five of these post-market clinical follow-up studies, which were successfully executed in multiple countries across Europe. All study materials were translated into the primary languages spoken in each study’s location.

Digital recruitment for all five studies was designed to target a population that had used the nasal spray products in the past 6 months.  

Each study called for participants to complete questionnaires, which were designed to be simple and intuitive to keep compliance rates high. This also allowed for participants to report any adverse events or side effects experienced from using the product.

‍

Results

Recruitment on all these studies was completed below projected budget. The studies reached completion before their targeted end dates, with an average duration of 48 days.

The sponsor was able to gain valuable insights into participant use and satisfaction with the product.

Case Study

Post-Market Clinical Follow-Up Studies in 5 European Countries

Infectious Disease
Respiratory/ENT
Download the PDF

Challenge

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

‍

Solution

IQVIA Consumer Health and ObvioHealth designed and conducted all five of these post-market clinical follow-up studies, which were successfully executed in multiple countries across Europe. All study materials were translated into the primary languages spoken in each study’s location.

Digital recruitment for all five studies was designed to target a population that had used the nasal spray products in the past 6 months.  

Each study called for participants to complete questionnaires, which were designed to be simple and intuitive to keep compliance rates high. This also allowed for participants to report any adverse events or side effects experienced from using the product.

‍

Results

Recruitment on all these studies was completed below projected budget. The studies reached completion before their targeted end dates, with an average duration of 48 days.

The sponsor was able to gain valuable insights into participant use and satisfaction with the product.

Case Study

Post-Market Clinical Follow-Up Studies in 5 European Countries

Infectious Disease
Respiratory/ENT
Download the PDF

Challenge

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

‍

Solution

IQVIA Consumer Health and ObvioHealth designed and conducted all five of these post-market clinical follow-up studies, which were successfully executed in multiple countries across Europe. All study materials were translated into the primary languages spoken in each study’s location.

Digital recruitment for all five studies was designed to target a population that had used the nasal spray products in the past 6 months.  

Each study called for participants to complete questionnaires, which were designed to be simple and intuitive to keep compliance rates high. This also allowed for participants to report any adverse events or side effects experienced from using the product.

‍

Results

Recruitment on all these studies was completed below projected budget. The studies reached completion before their targeted end dates, with an average duration of 48 days.

The sponsor was able to gain valuable insights into participant use and satisfaction with the product.

Case Study

Post-Market Clinical Follow-Up Studies in 5 European Countries

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

Download the PDF
Infectious Disease
Respiratory/ENT

Challenge

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

‍

Solution

IQVIA Consumer Health and ObvioHealth designed and conducted all five of these post-market clinical follow-up studies, which were successfully executed in multiple countries across Europe. All study materials were translated into the primary languages spoken in each study’s location.

Digital recruitment for all five studies was designed to target a population that had used the nasal spray products in the past 6 months.  

Each study called for participants to complete questionnaires, which were designed to be simple and intuitive to keep compliance rates high. This also allowed for participants to report any adverse events or side effects experienced from using the product.

‍

Results

Recruitment on all these studies was completed below projected budget. The studies reached completion before their targeted end dates, with an average duration of 48 days.

The sponsor was able to gain valuable insights into participant use and satisfaction with the product.

Back to Top
Case Study

Post-Market Clinical Follow-Up Studies in 5 European Countries

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

Infectious Disease
Respiratory/ENT
Download the PDF

Challenge

A multi-national European pharmaceutical and consumer health company required clinical data to validate the safety and performance of five of its nasal spray and allergy products post CE-mark, in accordance with MDR 2017/745 Annex XIV Part B.

‍

Solution

IQVIA Consumer Health and ObvioHealth designed and conducted all five of these post-market clinical follow-up studies, which were successfully executed in multiple countries across Europe. All study materials were translated into the primary languages spoken in each study’s location.

Digital recruitment for all five studies was designed to target a population that had used the nasal spray products in the past 6 months.  

Each study called for participants to complete questionnaires, which were designed to be simple and intuitive to keep compliance rates high. This also allowed for participants to report any adverse events or side effects experienced from using the product.

‍

Results

Recruitment on all these studies was completed below projected budget. The studies reached completion before their targeted end dates, with an average duration of 48 days.

The sponsor was able to gain valuable insights into participant use and satisfaction with the product.

Discover More Case Studies

Discover More News

Discover More White Papers

Discover More Blogs

Discover More Playbooks

Discover More Webinars

Discover More Events

Infectious Disease

Norovirus Vaccine Study​

VaxArt needed solutions for evaluating the safety and immunogenicity of its orally administered norovirus vaccine. Of particular importance was incorporating a way to quickly detect severe reactogenicity symptoms during the first week following vaccine administration. ​

› Read More
CNS

Treatment-Resistant Depression Study 

A global pharmaceutical company needed to understand the impact of a dissociative anesthetic on quality of life in patients with treatment-resistant depression. The company sought a way to gather high-quality data and carefully monitor suicidality. 

› Read More